Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development...

Bibliografske podrobnosti
Main Authors:	Ningning Yan, Ziheng Zhang, Sanxing Guo, Shujing Shen, Xingya Li
Format:	Article
Jezik:	English
Izdano:	Frontiers Media S.A. 2023-05-01
Serija:	Frontiers in Medicine
Teme:	liver cancer tyrosine kinase inhibitors MET savolitinib MET-TKI
Online dostop:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/full

Podobne knjige/članki

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
od: Ningning Yan, et al.
Izdano: (2023-07-01)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
od: Sun Min Lim, MD, PhD, et al.
Izdano: (2021-06-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
od: Yifan Zhang, et al.
Izdano: (2024-06-01)

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
od: Xiaolin Ren, et al.
Izdano: (2024-02-01)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
od: Kang Miao, et al.
Izdano: (2023-05-01)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
od: Shun Lu, MD, et al.
Izdano: (2022-10-01)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
od: Kexun Zhou, et al.
Izdano: (2023-11-01)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
od: Yu Zhang, et al.
Izdano: (2022-09-01)

Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis
od: Rui Deng, et al.
Izdano: (2024-08-01)

Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib
od: Yinyin Xue, et al.
Izdano: (2025-03-01)

Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report
od: Meng LU, et al.
Izdano: (2024-11-01)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
od: Wen Ye, et al.
Izdano: (2022-04-01)

Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer
od: Sen HAN, et al.
Izdano: (2020-07-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
od: Yu Yao, et al.
Izdano: (2023-01-01)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
od: Meng Fu, et al.
Izdano: (2022-08-01)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
od: Jiangfang Tian, et al.
Izdano: (2022-10-01)

Precision treatment paradigm: Genomic features and therapeutic implications in mesenchymal‐epithelial transition‐amplified gastric cancer
od: Yiyi Yu, et al.
Izdano: (2024-08-01)

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
od: Tejas Patil, MD, et al.
Izdano: (2024-02-01)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
od: El Darsa H, et al.
Izdano: (2020-10-01)

In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
od: Ji Yeon Song, et al.
Izdano: (2024-11-01)

MET in glioma: signaling pathways and targeted therapies
od: Fangling Cheng, et al.
Izdano: (2019-06-01)

Joint DNA-RNA-based NGS for diagnosis and treatment of a rare CD47-MET fusion lung adenocarcinoma which was immunoresistant and savoltinib-sensitive: a case report
od: Rulan Wang, et al.
Izdano: (2024-06-01)

Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance  in Non-small Cell Lung Cancer
od: Shilong SONG, et al.
Izdano: (2014-10-01)

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer
od: Yaolin Song, et al.
Izdano: (2021-09-01)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
od: Nam Ah Kim, et al.
Izdano: (2020-02-01)

Metabolic Profile Reveals the Immunosuppressive Mechanisms of Methionyl-Methionine in Lipopolysaccharide-Induced Inflammation in Bovine Mammary Epithelial Cell
od: Wei Lan, et al.
Izdano: (2021-03-01)

Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers
od: Han Yao, et al.
Izdano: (2022-08-01)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
od: Elena Michaels, et al.
Izdano: (2022-10-01)

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
od: Ming Zeng, et al.
Izdano: (2024-03-01)

IQGAP1 Is a Phosphotyrosine-Regulated Scaffold for SH2-Containing Proteins
od: Louise Thines, et al.
Izdano: (2023-02-01)

MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer
od: Limei YIN, et al.
Izdano: (2018-07-01)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
od: Jian Li, et al.
Izdano: (2022-04-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
od: Chen-Yu Hu, et al.
Izdano: (2019-12-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
od: Li Liu, et al.
Izdano: (2021-10-01)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
od: Daniel S Lefler, et al.
Izdano: (2022-12-01)

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
od: Yunhua Xu, et al.
Izdano: (2022-10-01)

Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer
od: ZHONG Cheng, et al.
Izdano: (2024-03-01)

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
od: Yukihiro Umeda, et al.
Izdano: (2025-01-01)

Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
od: Ying Wei, et al.
Izdano: (2023-03-01)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
od: Karen Koo, et al.
Izdano: (2023-03-01)